Maladi alzayme a se yon pwogresis maladi newolojik ki lakòz selil sèvo yo dejenere ak mouri, ki mennen nan yon bès nan memwa, panse, ak rezònman kapasite.
Se kòz ki pi komen pou demans, ki reprezante 60-80% nan tout ka yo.
Maladi a se finalman fatal, ak mwayèn esperans lavi apre dyagnostik la se 4-8 ane, byenke gen kèk moun ki ka viv jiska 20 ane ak maladi a.
Pousantaj mòtalite pou maladi alzayme a varye selon etid la ak popilasyon yo egzamine a.
Dapre asosyasyon alzaymè a, maladi alzaymè a se sizyèm kòz prensipal lanmò nan Etazini, epi li se senkyèm kòz prensipal lanmò pou moun ki gen laj 65 ak plis.
Nan lane 2019, maladi alzayme a te rapòte kòm kòz ki kache lanmò pou 121,9444 moun nan Etazini.
Li enpòtan pou note ke to mòtalite pou maladi alzayme a pa sèlman akòz maladi a li menm, men tou akòz konplikasyon ak lòt pwoblèm sante ki rive kòm rezilta maladi a.
Pandan maladi a ap pwogrese, moun yo ka gen difikilte pou yo fè aktivite lavi chak jou yo, tankou manje, benyen, ak abiye, ki kapab mennen nan malnitrisyon, enfeksyon, ak lòt pwoblèm sante.
Anplis de sa, moun ki gen maladi alzayme a ka gen plis chans pou yo tonbe, pou yo pran nemoni ak lòt enfeksyon.
Pandan ke pa gen aktyèlman okenn gerizon pou maladi alzayme a, gen tretman ki disponib ki ka ede jere sentòm yo ak amelyore kalite lavi.
Rechèch ap kontinye pou devlope nouvo tretman e finalman jwenn yon gerizon pou maladi sa a ki devaste.
Zhu B, Chen X, Li W, Zhou D: Effect of Alzheimer Disease on Prognosis of Intensive Care Unit (ICU) Patients: A Propensity Score Matching Analysis. Med Sci Monit. 2022, 28 (): e935397.
Almeida MC, Gomes Cde M, Nascimento LF: Spatial distribution of deaths due to Alzheimer's disease in the state of São Paulo, Brazil. Sao Paulo Med J. 2014, 132 (4): 199-204.
Aevarsson O, Svanborg A, Skoog I: Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Arch Neurol. 1998, 55 (9): 1226-32.
Breitner JC: Clinical genetics and genetic counseling in Alzheimer disease. Ann Intern Med. 1991, 115 (8): 601-6.
Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, Rasmussen SA, Roqué Figuls M, Alcolea D, Videla L, Barroeta I, Benejam B, Altuna M, Padilla C, Pegueroles J, Fernandez S, Belbin O, Carmona-Iragui M, Blesa R, Lleó A, Bejanin A, Fortea J: Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Netw Open. 2022, 5 (5): e2212910.
['Avètisman: medikal']
['Sit entènèt sa a se pou rezon edikasyonèl ak enfòmasyon sèlman e li pa bay konsèy medikal oswa sèvis pwofesyonèl.']
['Enfòmasyon yo bay la pa dwe itilize pou fè dyagnostik oswa trete yon pwoblèm sante oswa maladi, e moun k ap chèche konsèy medikal pèsonèl ta dwe konsilte yon doktè ki gen lisans.']
['Tanpri note ke rezo neural ki jenere repons pou kesyon yo, pa egzat sitou lè li rive pou kontni nimerik. pa egzanp, kantite moun ki te dyagnostike ak yon maladi espesifik.']
['Toujou chèche konsèy doktè ou oswa lòt founisè sante ki kalifye konsènan yon kondisyon medikal. Pa janm meprize konsèy medikal pwofesyonèl oswa reta nan chèche li paske nan yon bagay ou te li sou sit entènèt sa a. Si ou panse ou ka gen yon ijans medikal, rele 911 oswa ale nan sal ijans ki pi pre a imedyatman. Pa gen okenn relasyon doktè-pasyan ki kreye pa sit entènèt sa a oswa itilizasyon li yo. Ni BioMedLib ni anplwaye li yo, ni okenn kontribitè nan sit entènèt sa a, fè okenn reprezantasyon, eksprime oswa enplisit, ki gen rapò ak enfòmasyon yo bay isit la oswa pou itilize li yo.']
['Avètisman: dwa otè']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) bay rekou pou mèt copyright ki kwè ke materyèl ki parèt sou entènèt la vyole dwa yo anba lwa copyright Etazini. ']
['Si ou kwè ak tout konfyans ke nenpòt kontni oswa materyèl ki disponib an koneksyon avèk sit entènèt nou an oswa sèvis vyole copyright ou, ou (oswa ajan ou) ka voye nou yon avi pou mande pou retire kontni an oswa materyèl la, oswa aksè a li bloke.']
['Anons yo dwe voye alekri pa imel (gade seksyon "Kontak" pou adrès imel)']
['DMCA mande pou avi ou sou vyolasyon dwa otè a genyen enfòmasyon sa yo: (1) deskripsyon travay ki gen dwa otè a ki sijè vyolasyon an; (2) deskripsyon kontni ki vyole dwa otè a ak enfòmasyon ki sifi pou pèmèt nou jwenn kontni an; (3) enfòmasyon pou kontakte ou, ki gen ladan adrès ou, nimewo telefòn ou ak adrès imel ou; (4) yon deklarasyon ou fè ki di ou gen bon lafwa ke kontni an nan fason ou pote plent la pa otorize pa mèt pwopriyete dwa otè a, oswa ajan li, oswa pa operasyon nenpòt lwa; ']
['(5) yon deklarasyon ou siyen sou penalite fo temwayaj ke enfòmasyon ki nan notifikasyon an egzat e ke ou gen otorite pou fè respekte dwa otè yo ke yo reklame ke yo vyole yo;']
['e (6) yon siyati fizik oubyen elektwonik mèt copyright la oubyen yon moun ki otorize pou aji sou non mèt copyright la. ']
['Si ou pa bay tout enfòmasyon ki anwo yo, sa ka fè ke nou pa trete plent ou a byen vit.']
['Kontak']
['Tanpri voye nou yon imèl avèk nenpòt kesyon / sijesyon.']
How deadly is alzheimer?
Alzheimer's disease is a progressive neurological disorder that causes brain cells to degenerate and die, leading to a decline in memory, thinking, and reasoning skills.
It is the most common cause of dementia, accounting for 60-80% of all cases.
The disease is ultimately fatal, with the average life expectancy after diagnosis being 4-8 years, although some people can live up to 20 years with the disease.
The mortality rate for Alzheimer's disease varies depending on the study and the population being examined.
According to the Alzheimer's Association, Alzheimer's disease is the sixth leading cause of death in the United States, and it is the fifth leading cause of death for those aged 65 and older.
In 2019, Alzheimer's disease was reported as the underlying cause of death for 121,9444 people in the United States.
It is important to note that the mortality rate for Alzheimer's disease is not solely due to the disease itself, but also due to complications and other health issues that arise as a result of the disease.
As the disease progresses, individuals may experience difficulty with activities of daily living, such as eating, bathing, and dressing, which can lead to malnutrition, infections, and other health problems.
Additionally, individuals with Alzheimer's disease may be at an increased risk of falls, pneumonia, and other infections.
While there is currently no cure for Alzheimer's disease, there are treatments available that can help manage symptoms and improve quality of life.
Research is ongoing to develop new treatments and ultimately find a cure for this devastating disease.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['sou']
['BioMedLib itilize òdinatè otomatik (algoritm aprantisaj machin) pou jenere pè kesyon ak repons.']
['Nou kòmanse ak 35 milyon piblikasyon biomedik de PubMed/Medline. tou, paj entènèt de RefinedWeb.']
